Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: Toxicity and efficacy trends
Pediatric Blood & Cancer, 04/27/2012
Couec ML et al. – Bevacizumab–related acute toxicity appears to be low in children, even in combination with irinotecan. Further prospective trials are required to confirm the hypothetical efficacy of bevacizumab and to assess the risk of long–term toxicity especially in the youngest children.